WO1996007432A1 - Transfer of molecules into the cytosol of cells - Google Patents
Transfer of molecules into the cytosol of cells Download PDFInfo
- Publication number
- WO1996007432A1 WO1996007432A1 PCT/NO1995/000149 NO9500149W WO9607432A1 WO 1996007432 A1 WO1996007432 A1 WO 1996007432A1 NO 9500149 W NO9500149 W NO 9500149W WO 9607432 A1 WO9607432 A1 WO 9607432A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cytosol
- compound
- cells
- molecules
- released
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to a method for introducing molecules in cells by disrupting endosomal and lysosomal membranes using photodynamic treatment, without killing the majority of the cells by the photodynamic treatment.
- porphyrins and many other photosensitizing compounds induce cytotoxic effects on cells and tissues. These effects are based upon the fact that the photosensitizing compound upon light exposure releases singlet '0 2 which decomposes the membranes of the cells and cell structures and eventually kill the cells if the destruction is extensive. These effects have been utilized to treat several types of neoplastic diseases.
- the treatment is named photodynamic therapy (PDT) and is based on injection of a photosensitizing and tumorlocalizing dye followed by exposure of the tumor region to light.
- PDT photodynamic therapy
- the cytotoxic effect is mediated mainly through the formation of singlet oxygen. This reactive intermediate has a very short lifetime in cells ( ⁇ 0.04 ⁇ s).
- the object of the present invention is thus to provide a method to transport molecules into cytosol of living cells, in culture or in tissues, by exposing the cells to a photoactivatable compound, the molecule(s) which is (are) to be transported into the cytosol, both of which uptake may be facilitated by various carriers, exposing the cell to light of suitable wavelength and energi to disrupt the endosomal and lysosomal membranes and release the molecules into the cytosol without destroying the f nctionality of the majority of the cells.
- the photosensitizer and the molecule(s) which is (are) to be transported into the cytosol may be conjugated to or applied separately together with suitable carriers, optionally facilitating the uptake of the molecules of interest.
- the present invention relates to a method for transporting any molecules into the cytosol of living cells after which the molecules shall be available in the cytosol and the cell shall maintain its functionability. This is performed by exposing the cell(s) to a photoactivatable compound which is taken up by the cell and will be located in endosomes, lysosomes or other cellular compartments, conjugated to or separately together with carrier molecules, targeting immunoglobulins and the molecules to be transported into the cytosol and expose the cells to light of suitable wavelength to activate the photosentizing compound, such that only the endosomal, lysosomal or other cellular compartment membranes are ruptured and the molecules released in the cytosol without the cell loosing its functionability by the action of the photoactivated compound and possible action of the enosomal/lysosomal content.
- Fig. l represents illustration of how molecules can be introduced into the cellular cytosol by means of the present invention.
- the photosensitizer (S) and the molecules of choice (M) are endocytosed by the cells (I, illustrates the invagination of the plasma membrane initiating the endocytic process) and both substances end up in the same vesicles
- Fig.2. illustrates protein synthesis in NHIK 3025 cells after treatment with gelonin in the absence or presence of TPPS 2a and 50 sec light exposure. Symbols: Q, TPPS 2a + light; •. - TPPS 2a - light; v, + TPPS 2a
- Fig.3. shows dose-response curves for cells treated with TPPS 2a and light only (O) or in combination with 0.2 ⁇ g/ml ( v) or 2.0 ⁇ g/ml gelonin as described Fig.2;
- Fig.4. shows protein synthesis in NHIK 3025 cells after treatment with 3,2 ⁇ g ml TPPS 2a and light in the absence or presence of 0,2 ⁇ g/ml gelonin. Symbols: ⁇ , TPPS ⁇ - gelonin; O, TPPS 2a + gelonin. The cells were treated with TPPS 2a in the absence or presence of gelonin overnight and exposed to the indicated doses of light. Protein synthesis was measured by measuring incorporation of 3 [HJleucine into proteins.
- Fig. 5 illustrates protein synthesis in V79 cells after treatment with 25 ⁇ g/ml AlPcS 2 and light in the absence and presence of 1 ⁇ g/ml gelonin. Symbols: • Photosensitizer + toxin; O photosensitizer,
- Fig. 6 illustrates protein synthesis in HI 46 cells after treatment with 0,3 ⁇ g/ml TPPS 2a and light in the absence and presence of 1 ⁇ g/ml gelonin. Symbols: as in Fig. 5,
- Fig. 7 illustrates protein synthesis in V79 cells after treatment with 1 ⁇ g/ml TPPS 2a and light in the absence and presence of 1 ⁇ g/ml gelonin.
- Fig. 8 illustrates protein synthesis in NHIK3025 cells after treatment with 3,2 ⁇ g/ml TPPS 2a and light in the absence and presence of 1 ⁇ g/ml agrostin. Symbols: as in Fig. 5,
- Fig. 9 illustrates protein synthesis in NHIK3025 cells after treatment with 3,2 ⁇ g/ml TPPS 2a and light in the absence and presence of 1 ⁇ g/ml saporin. Symbols: as in Fig. 5,
- Fig. 10 illustrates protein synthesis in NHIK3025 cells after treatment with
- Fig. 11 illustrates protein synthesis in COS-7 cells after treatment with 3 ⁇ g/ml TPPS 2a and light in the absence and presence of 1 ⁇ g/ml gelonin. Symbols: as in Fig. 5,
- Fig. 12 illustrates protein synthesis in NHIK 3025 cells after treatment with gelonin in the absence or presence of TPPS4 and 50 sec light exposure. Symbols: ⁇ TPPS 4 + light; ⁇ - TPPS 4 - light; 0 + RPPS 4 - light. The cells were treated with 75 ⁇ g/ml TPPS 4 and the indicated concentration of gelonin overnight and in all cases given the same dose of light. Protein synthesis was measured by measuring incorporation of 3 lHJleucine into proteins, 24 h after light exposure; and
- Fig. 13 illustrates protein synthesis in OHS cells after treatment with 3 ⁇ g/ml TPPS 2a for 18 hours followed by 4 hours in the absence of TPPS 2a and in the absence or presence of 3 ⁇ g/ml gelonin before exposure to light.
- the cells were incubated for the same 4 hours in 50 ⁇ M chloroquine or 10 mM NH 4 C1 to inhibit lysosomal protein degration.
- the introduction of molecules into the cellular cytoplasm is achieved by fjrsl exposing the cells or tissue to a photosensitizing dye, the molecule(s) which one wants to deliver into the cytosol of the cells together with, or not carrier molecules and immunoglobins, all of which should preferentially localize in endosomes and/or lysosomes.
- the cells or tissue is exposed to light of suitable wavelengths and energies inducing a photodynamic reaction. This photodynamic reaction will lead to disruption of lysosomal and/or endosomai membranes and the contents of these vesicles will be released into the cytosol.
- Fig.1 The principles of the present invention are illustrated in Fig.1. It is necessary that the photosensitizer and the molecule to be introduced into the cells are located in the same compartments. It should also be emphasized that externally added molecules may accumulate in intracellular compartments other than lysosomes and endosomes, e.g. Golgi apparatus and endoplasmic reticulum. In such cases, photosensitizing compounds located in the same compartments may in combination with light be used for the same purposes provided that the combination of light dosis and photosensitizing compound does not destroy the functionality of the cells.
- the present invention is based on our in vitro demonstration, that a photosensitizer, for example TPPS 2a , (tetraphenylporphine with 2 sulfonate groups on adjacent phenyl groups) in combination with light can induce release of functionally intact lysosomal contents without killing a large fraction of the cells.
- a photosensitizer for example TPPS 2a
- TPPS 2a tetraphenylporphine with 2 sulfonate groups on adjacent phenyl groups
- Such vectors can be tissue or cell specific antibodies or other ligands that bind to the cell surface, thus increasing the uptake of the photosensitizer through receptor-mediated endocytosis.
- Another vector could be the use of reconstituted LDL-particles. These particles are also taken up by receptor-mediated endocytosis.
- LDL particle and the binding to the LDL-particles can in this way be increased compared to prebinding to native LDL.
- the present invention is not restricted to in vitro use, but may as well be used in vivo, either by in situ treatment or by ex vivo treatment followed by injection of the treated cells.
- the uptake into endosomes and lysosomes can be enhanced in the same manner as described above for in vitro treatment. All tissues can be treated as long as the photosensitizer is taken up by the target cells and the light can be properly delivered.
- the present invention is based on both a photosensitizer and light.
- the light must be absorbed by the photosensitizer or indirectly induce an excited state of the photosensitizer.
- the wavelength region of use will therefore depend on the photosensitizer.
- the exposure light does not need to be monochromatic or collimated. Every light source emitting the appropriate wavelengths can be used.
- photosensitizers accumulate preferentially in neoplastic tissues, the selectivity for a tumor over the surrounding tissue being usually a factor of 2-3, but this factor may in some cases, such as for brain tissues, be higher, i.e. up to 30.
- Molecules which may be of clinical interest for treatment of cancer, but is restricted by a low or no uptake into the cytosol can be introduced into the cytosol by means of the present invention.
- Gelonin as exemplified below, is an example of such a molecule.
- Several other molecules, either alone or linked to other molecules e.g. antibodies, transferrin, photosensitizers, apoB on reconstituted LDL-particles) can be used.
- the advantage of such a combination treatment would be 1) enhanced cytotoxic effect in deeper layers of the tumor tissues since low and subtoxic doses of light are sufficient for disruption of lysosomes and endosomes; 2) enhanced specificity of the toxin since PDT is only given to the area of tumor localization.
- Gene therapy i.e. therapeutic transfer of genes to the patients cells
- Gene therapy is promising as a method for treating many genetic disorders such as cancer, cystic fibrosis, cardiovascular diseases and many other diseases.
- the main problem today is the transfection which must occur in vivo or in some cases can be performed ex vivo.
- the most frequently used vector i.e. the structure that helps delivering the DNA molecules into the cells, is different types of viruses, especially retro- and adenoviruses.
- the drawbacks of such methods are low stability of the vector, limited specificity, low yield and introduction of virus- DNA into human cells.
- DNA either as antisense DNA or whole genes, can be introduced into cells by the aid of photochemically induced disruption of endosomes and/or lysosomes.
- the treatment can be performed in vivo.
- the present invention can be used to introduce a wide variety of molecules into cells in culture, e.g., genes, antibodies, manipulated proteins and compounds usually not permeable to the plasma membrane.
- Example 1 This example demonstrates that photodynamic treatment releases a protein synthesis inhibiting compound into the cytosol.
- a number of plant toxins kills cells by entering the cytosol and inactivating enzymatically the ribosomal function.
- the most cytotoxic plant proteins consist of 2 polypeptide chains, A and B, linked together by disulfide bridges.
- the function of chain B is to bind the protein to the surface of the cells, while chain A contains the enzymatic activity.
- Gelonin is a plant toxin which efficiently inhibits protein synthesis in cell-free systems, but has little or no effect on intact cells. The low cytotoxic effect on intact cells is probably due to the lack of a B chain in gelonin.
- NHIK 3025 cells were incubated with TPPS ⁇ (Formula I) and gelonin, separately or together for 18 h, followed by 1 h in TPPS 2a and gelonin- free medium before the cells were exposed to light. Protein synthesis was measured 24 h after exposure to light.
- TPPS ⁇ and light can be used to introduce functionally intact macromolecules into the cellular cytosol.
- Example 2 This example illustrates how the dose of light (with the wavelength which is absorbed by the dye) can be used to decide the size of the surviving cell fraction.
- NHIK 3025 Solutions were incubated with TPPS 2a and geloning according to the design of Example 1.
- Clonogenic survivial of the cells was measured 24 h after exposure to light. As illustrated in Fig. 3 virtually all cells were killed with TPPS 2a and light when the light exposure was increased. This is in accordance with prior art regarding killing unwanted cells with PDT.
- gelonin When gelonin is added the survival rate drops due to the inhibiting effect of gelonin on protein synthesis, showing that gelonin now is released in the cytosol. Increased concentration of added gelonin leads to more gelonin in the cytosol, as indicated by an increased sensitivity of the cells to photo inactivation.
- the present invention thus offers the possibility to set a level of survival in each case and select a combination of photosensitizing compound and light exposure which will keep the wanted fraction of cells alive.
- Example 3 This example illustrates how changing light doses control the amount of gelonin released in the cytosol, as determined by the relative protein synthesis.
- NHIK 3025 cells were incubated with TPPS 2a and gelonin according to the design of Example 1.
- Figure 4 shows that light doses above the toxic dose of 50 sec increased the gelonin fraction in cytosol as determined by the relative protein synthesis.
- Example 4-11 demonstrates use of the method according to the invention on different cell lines and with different photosensitizers and toxins.
- the intracellular location of the photosensitizers are lysosomal (TPPS 4 , TPPS 2a , AlPcS 2a ) and extralysosomal (3-THPP).
- TPPS 4 lysosomal
- TPPS 2a aluminium phtalocyanine with 2 sulfonate groups on adjacent phenyl rings
- TPPS 4 for meso-tetraphenylporphine with 4 sulfonate groups
- TPPS2a for meso-tetraphenylporphine with 2 sulfonate groups on adjacent phenyl rings; 3-.
- THPP for tetrahydroxylphenyl porphine.
- the used cell lines are carcinoma cells in situ from human cervix (NHIK 3025), Chinese hamster lung fibroblasts (V 79), SV40-transformed African Green monkey kidney (CV1 -simian fibroblasts- like cells) (Cos-7) human osteosarcoma cells (OHS) and small cell lung cancer cells (HI 46). All experiments were designed as in Example 1.
- Example 4 This example relates to use of the photosensitizer AlPcS 2a in V79 cells with/without gelonin as the toxin (Fig. 5).
- a specific light dose irradiation time
- gelonin the protein synthesis is profoundly reduced.
- Sulfonated aluminium phtalocyanines as sensitizers for photochemotherapy. Effects of small light doses on localization, dye fluorescence and photosensitivity in V79 cells. Int. J. Cancer 58: 865-870).
- Example 5 This example demonstrates transport of the toxin gelonin into HI 46 cells without essentially affecting the viability of the cells.
- TPPS 2a is known to be lysosomal located in the cell.
- Example 6 This example demonstrates the method according to the invention in V79 cells using TPPS 2a as photosensitizer (Fig. 7).
- Example 7 This example demonstrates transport into NHIK 3025 cells of the toxin agrostin using the photosensitizer TPP 2a (Fig. 8).
- Example 8 This example demonstrates transport of the toxin saporin into NHIK 3025 cells using TPP 2a (Fig. 9).
- Example 9 This is a comparison example demonstrating that when a photosensitizer (3-THPP) which does not enter endocytic vesicles (i.e. endosomes and lysosomes) (Peng, Q., Danielsen, H.E. and Moan, J. ( 1994) Potent photosensitizers for photodynamic therapy of cancer: Applications of confocal laser scanning microscopy for fluorescence detection of photosensitizing fluorophores in neoplastic cells and tissues. In: Proceedings of Microscopy, Holography, and Interferometry in Biomedicine. SPIE Vol. 2083:71 -82), there is no significant difference between the protein synthesis effect of 3THPP with or without gelonin (Fig. 10). Thus gelonin is not transported into the cytosol of the cells.
- Example 10 This example demonstrates the transport of gelonin into COS-7 cells by using TPPS 2a according to the invention (Fig. 1 1).
- Example 1 1 This example demonstrates the transport of gelonin into OHS cells by using TPPS 2a according to the invention. (Fig. 13). In this cell line there is a considerable protein degradation in the lysosomes, which in the present example is inhibited by incubating the cells for 4 hours in either 50 ⁇ M chloroquine or 10 mM NH 4 C1.
- Example 12 Similar to example 1 this example demonstrates transport of gelonin into NHIK 3025 cells as a function of the gelonin concentration when the cells were incubated with TPPS 4 and different concentrations of gelonin, and exposed to light (Fig. 12). When the cells were incubated with gelonin alone and exposed to light, or incubated with TPPS4 and gelonin without exposure to light, no transport of gelonin into the cells was obtained.
- the examples demonstrate that different molecules can be introduced into the cells cytosol in a wide variety of cells using different pkotosensitizers and doses of light.
- Exogenous molecules can be introduced to the cellular cytosol after doses of photosensitizers and light which do not kill the cells, as long as the molecules to be introduced and the photosensitizers are transported to the same cellular compartments.
- the photochemical effect on a biological compartment is dependent upon the amount of photosensitizers in that compartment, the dose of light applied and the spectral properties of the light source.
- the best way to evaluate photochemical effects on cells in culture is therefore to measure cell survival 24 hours or more after treatment. There is a good correlation between the effect on cell killing and inhibition of protein synthesis, 24 hours after treatments as presented above (data not shown).
Abstract
Description
Claims
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU9800153A HU222984B1 (en) | 1994-09-08 | 1995-09-04 | In vitro method for transfer of molecules into the cytosol of living cells by photosensiting compounds |
CZ97658A CZ65897A3 (en) | 1994-09-08 | 1995-09-04 | Method of transferring molecules into cytosol of cells, set for making the method and a mixture for modification neoplastic or other cellular processes |
NZ293008A NZ293008A (en) | 1994-09-08 | 1995-09-04 | Photoactivatable compound-carrier molecule conjugates for transfer into a cell cytosol where they are taken up by endosomes and lysosomes |
AU35347/95A AU700797B2 (en) | 1994-09-08 | 1995-09-04 | Transfer of molecules into the cytosol of cells |
MX9701676A MX9701676A (en) | 1994-09-08 | 1995-09-04 | Transfer of molecules into the cytosol of cells. |
DE69524238T DE69524238T2 (en) | 1994-09-08 | 1995-09-04 | TRANSFER OF MOLECULES INTO THE CYTOSOL OF CELLS BY PHOTOSENSITIZING SUBSTANCES |
BRPI9508825A BRPI9508825B8 (en) | 1994-09-08 | 1995-09-04 | process of transferring molecules to the cytosol of cells, composition and kit |
US08/793,794 US5876989A (en) | 1994-09-08 | 1995-09-04 | Transfer of molecules into the cytosol of cells |
EP95932244A EP0783323B1 (en) | 1994-09-08 | 1995-09-04 | Transfer of molecules into the cytosol of cells by photosensitizing compounds |
AT95932244T ATE209507T1 (en) | 1994-09-08 | 1995-09-04 | TRANSFER OF MOLECULES INTO THE CYTOSOL OF CELLS BY PHOTOSENSITIZING SUBSTANCES |
JP50940496A JP4148328B2 (en) | 1994-09-08 | 1995-09-04 | Transfer of compounds to the cell cytosol |
CA2199290A CA2199290C (en) | 1994-09-08 | 1995-09-04 | Transfer of molecules into the cytosol of cells |
KR10-2003-7005142A KR100529967B1 (en) | 1994-09-08 | 1995-09-14 | Composition for transfer of molecules into the cytosol of cells |
FI970983A FI121328B (en) | 1994-09-08 | 1997-03-07 | Transfer of molecules to the cytosol in cells |
HK98103468A HK1004110A1 (en) | 1994-09-08 | 1998-04-24 | Transfer of molecules into the cytosol of cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NO943327 | 1994-09-08 | ||
NO943327A NO180167C (en) | 1994-09-08 | 1994-09-08 | Photochemical method for introducing molecules into the cytosol of cells |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/793,794 A-371-Of-International US5876989A (en) | 1994-09-08 | 1995-09-04 | Transfer of molecules into the cytosol of cells |
US09/144,750 Continuation-In-Part US6680301B2 (en) | 1994-09-08 | 1998-09-01 | Transfer of molecules into the cytosol of cells |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996007432A1 true WO1996007432A1 (en) | 1996-03-14 |
Family
ID=19897382
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NO1995/000149 WO1996007432A1 (en) | 1994-09-08 | 1995-09-04 | Transfer of molecules into the cytosol of cells |
Country Status (20)
Country | Link |
---|---|
US (3) | US5876989A (en) |
EP (1) | EP0783323B1 (en) |
JP (1) | JP4148328B2 (en) |
KR (2) | KR100395615B1 (en) |
CN (1) | CN1222309C (en) |
AT (1) | ATE209507T1 (en) |
AU (1) | AU700797B2 (en) |
BR (1) | BRPI9508825B8 (en) |
CA (1) | CA2199290C (en) |
CZ (1) | CZ65897A3 (en) |
DE (1) | DE69524238T2 (en) |
ES (1) | ES2163527T3 (en) |
FI (1) | FI121328B (en) |
HK (1) | HK1004110A1 (en) |
HU (1) | HU222984B1 (en) |
MX (1) | MX9701676A (en) |
NO (1) | NO180167C (en) |
NZ (2) | NZ509519A (en) |
PT (1) | PT783323E (en) |
WO (1) | WO1996007432A1 (en) |
Cited By (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000054802A2 (en) * | 1999-03-15 | 2000-09-21 | Photocure Asa | Method of expressing antigens on the surface of antigen presenting cells by photochemical internalization |
WO2002044395A1 (en) * | 2000-11-29 | 2002-06-06 | Pci Biotech As | Photochemical internalization for virus-mediated molecule delivery into the cyosol |
WO2002062989A2 (en) * | 2001-02-08 | 2002-08-15 | Sequitur, Inc. | Methods of light activated release 0f ligands from endosomes |
US6680301B2 (en) | 1994-09-08 | 2004-01-20 | Photocure As | Transfer of molecules into the cytosol of cells |
US7141044B2 (en) | 2001-12-11 | 2006-11-28 | Ekos Corporation | Alternate site gene therapy |
US7223600B2 (en) | 2000-11-29 | 2007-05-29 | The Norwegian Radium Hospital Research Foundation | Photochemical internalization for delivery of molecules into the cytosol |
WO2008007073A2 (en) | 2006-07-11 | 2008-01-17 | Pci Biotech As | Method for introducing sirna into cells by photochemical internalisation |
US7320885B1 (en) * | 1999-09-09 | 2008-01-22 | Toudai Tlo, Ltd. | Method of perforating membrane and apparatus therefor |
US7662807B2 (en) | 2001-08-30 | 2010-02-16 | The Norwegian Radium Hospital Research Foundation | Sulphonated meso-tetraphenyl chlorins |
WO2011018636A2 (en) | 2009-08-14 | 2011-02-17 | Pci Biotech As | Photochemical internalization method |
WO2011018635A2 (en) | 2009-08-14 | 2011-02-17 | Pci Biotech As | Photosensitizing compositions |
US8690818B2 (en) | 1997-05-01 | 2014-04-08 | Ekos Corporation | Ultrasound catheter for providing a therapeutic effect to a vessel of a body |
WO2014139597A1 (en) | 2013-03-15 | 2014-09-18 | Pci Biotech As | Method |
US8852166B1 (en) | 2002-04-01 | 2014-10-07 | Ekos Corporation | Ultrasonic catheter power control |
WO2015028541A1 (en) * | 2013-08-28 | 2015-03-05 | Pci Biotech As | Antigen delivery device and method |
WO2015154832A1 (en) | 2014-04-11 | 2015-10-15 | Pci Biotech As | Method of treating melanoma |
US9241996B2 (en) | 2008-06-30 | 2016-01-26 | Pci Biotech As | Photochemical internalisation of kinase inhibitors |
WO2016030529A1 (en) | 2014-08-28 | 2016-03-03 | Pci Biotech As | Compound and method |
US9592250B2 (en) | 2002-02-01 | 2017-03-14 | Life Technologies Corporation | Double-stranded oligonucleotides |
US9777275B2 (en) | 2002-02-01 | 2017-10-03 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
US9901636B2 (en) | 2012-05-15 | 2018-02-27 | Pci Biotech As | Conjugate of a photosensitiser and chitosan and uses thereof |
WO2018069536A1 (en) | 2016-10-14 | 2018-04-19 | Pci Biotech As | Treatment of cholangiocarcinoma with tpcs-2a induced photochemical internalisation of gemcitabine |
WO2019145419A1 (en) * | 2018-01-24 | 2019-08-01 | Pci Biotech As | Method |
US10610582B2 (en) | 2013-08-28 | 2020-04-07 | Pci Biotech As | Compound and method for vaccination and immunisation |
US10656025B2 (en) | 2015-06-10 | 2020-05-19 | Ekos Corporation | Ultrasound catheter |
WO2020217226A1 (en) | 2019-04-25 | 2020-10-29 | Dcprime B.V. | Methods of tumor vaccination |
US10926074B2 (en) | 2001-12-03 | 2021-02-23 | Ekos Corporation | Catheter with multiple ultrasound radiating members |
GB202101726D0 (en) | 2021-02-08 | 2021-03-24 | Pci Biotech As | Method |
US11027017B2 (en) | 2015-03-05 | 2021-06-08 | Pci Biotech As | PCI method for generating immune respose to antigenic molecule using checkpoint inhibitor and TLR3 ligand |
US11071778B2 (en) | 2018-07-16 | 2021-07-27 | Dcprime B.V. | Combination product for use in tumor vaccination |
WO2021191870A1 (en) | 2020-03-27 | 2021-09-30 | Dcprime B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
WO2021191871A1 (en) | 2020-03-27 | 2021-09-30 | Dcprime B.V. | In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
WO2022097068A1 (en) | 2020-11-05 | 2022-05-12 | Dcprime B.V. | Use of tumor-independent antigens in immunotherapies |
WO2022190058A1 (en) | 2021-03-12 | 2022-09-15 | Dcprime B.V. | Methods of vaccination and use of cd47 blockade |
WO2023073116A1 (en) | 2021-10-27 | 2023-05-04 | Pci Biotech As | Method |
US11648287B2 (en) | 2017-11-10 | 2023-05-16 | Academisch Medisch Centrum | Composition for the treatment of intracellular bacterial infection |
US11672553B2 (en) | 2007-06-22 | 2023-06-13 | Ekos Corporation | Method and apparatus for treatment of intracranial hemorrhages |
US11925367B2 (en) | 2007-01-08 | 2024-03-12 | Ekos Corporation | Power parameters for ultrasonic catheter |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6210356B1 (en) * | 1998-08-05 | 2001-04-03 | Ekos Corporation | Ultrasound assembly for use with a catheter |
US6176842B1 (en) * | 1995-03-08 | 2001-01-23 | Ekos Corporation | Ultrasound assembly for use with light activated drugs |
WO1998041158A1 (en) * | 1997-03-19 | 1998-09-24 | Lucid Technologies, Inc. | Cellular surgery utilizing confocal microscopy |
US6676626B1 (en) | 1998-05-01 | 2004-01-13 | Ekos Corporation | Ultrasound assembly with increased efficacy |
WO1999034831A1 (en) * | 1998-01-05 | 1999-07-15 | University Of Washington | Enhanced transport using membrane disruptive agents |
US6399769B1 (en) * | 1998-01-20 | 2002-06-04 | Kimberly-Clark Worldwide, Inc. | Method of making sulfanatophenyl substituted porphines |
JP5610659B2 (en) * | 2000-07-21 | 2014-10-22 | ルバンス セラピュティックス インク.Revance Therapeutics,Inc. | Multi-component biological transport system |
US20040220100A1 (en) * | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
US20020098472A1 (en) * | 2000-11-30 | 2002-07-25 | Erlach Julian Van | Method for inserting a microdevice or a nanodevice into a body fluid stream |
US20020137901A1 (en) * | 2001-01-22 | 2002-09-26 | Cavanaugh Philip Gerard | Synthesis, and photodynamic therapy-mediated anti-cancer, and other uses of chlorin e6-transferrin |
WO2003000297A1 (en) * | 2001-06-20 | 2003-01-03 | Sumitomo Pharmaceuticals Company, Limited | Method of promoting nucleic acid transfer |
US20030166282A1 (en) * | 2002-02-01 | 2003-09-04 | David Brown | High potency siRNAS for reducing the expression of target genes |
US20040248094A1 (en) * | 2002-06-12 | 2004-12-09 | Ford Lance P. | Methods and compositions relating to labeled RNA molecules that reduce gene expression |
GB0215534D0 (en) * | 2002-07-04 | 2002-08-14 | Ecole Polytech | Selective photochemotherapy using oligonucleotide targeting agents |
US20040029275A1 (en) * | 2002-08-10 | 2004-02-12 | David Brown | Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs |
US6921371B2 (en) * | 2002-10-14 | 2005-07-26 | Ekos Corporation | Ultrasound radiating members for catheter |
JP2006517790A (en) * | 2003-01-09 | 2006-08-03 | インヴィトロジェン コーポレーション | Cellular delivery and activation of polypeptide-nucleic acid complexes |
US7332477B2 (en) * | 2003-07-10 | 2008-02-19 | Nitto Denko Corporation | Photocleavable DNA transfer agent |
WO2005032597A1 (en) * | 2003-09-29 | 2005-04-14 | Nitto Denko Corporation | Biodegradable polyacetals for in vivo polynucleotide delivery |
EP1696034A4 (en) * | 2003-12-19 | 2006-12-27 | Dainippon Sumitomo Pharma Co | Novel method of nucleic acid transfer |
CN1946431B (en) | 2004-03-03 | 2011-12-07 | 雷文斯治疗公司 | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
CN101083907B (en) * | 2004-03-03 | 2012-10-10 | 雷文斯治疗公司 | Compositions and methods for topical diagnostic and therapeutic transport |
US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
GB0415263D0 (en) * | 2004-07-07 | 2004-08-11 | Norwegian Radium Hospital Res | Method |
US20060094781A1 (en) * | 2004-11-04 | 2006-05-04 | Syneron Medical Ltd. | Method of treating extracellular matrix |
FR2877943B1 (en) * | 2004-11-16 | 2008-09-05 | Univ De Coimbra | NOVEL PORPHYRINE DERIVATIVES, IN PARTICULAR CHLORINES AND / OR BACTERIOCHLORIN, AND THEIR PHOTODYNAMIC THERAPY APPLICATIONS |
EP1861112A4 (en) | 2005-03-03 | 2009-07-22 | Revance Therapeutics Inc | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
RU2007136617A (en) * | 2005-03-03 | 2009-04-10 | Риванс Терапьютикс, Инк. (Us) | COMPOSITION AND METHOD FOR LOCAL USE AND TRANSMISSION OF OLIGOPEPTIDE |
US7674452B2 (en) * | 2005-03-16 | 2010-03-09 | Nitto Denko Corporation | Polymer coating of cells |
BRPI0501037B8 (en) | 2005-03-18 | 2021-07-27 | Fund De Amparo A Pesquisa Do Estado De Sao Paulo | crotamine use and composition |
EP1948230A4 (en) * | 2005-11-17 | 2010-03-10 | Revance Therapeutics Inc | Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins |
US7718193B2 (en) * | 2006-03-16 | 2010-05-18 | University Of Washington | Temperature- and pH-responsive polymer compositions |
EP2099496A2 (en) * | 2006-12-08 | 2009-09-16 | Massachusetts Institute of Technology | Delivery of nanoparticles and/or agents to cells |
US20100093639A1 (en) * | 2006-12-29 | 2010-04-15 | Revance Therapeutics, Inc. | Transport Molecules Using Reverse Sequence HIV-TAT Polypeptides |
NZ598039A (en) * | 2006-12-29 | 2013-08-30 | Revance Therapeutics Inc | Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from HIV-TAT |
US7981688B2 (en) | 2007-03-08 | 2011-07-19 | University Of Washington | Stimuli-responsive magnetic nanoparticles and related methods |
US20090187137A1 (en) * | 2007-12-14 | 2009-07-23 | Kim Volz | Ultrasound pulse shaping |
US8426214B2 (en) * | 2009-06-12 | 2013-04-23 | University Of Washington | System and method for magnetically concentrating and detecting biomarkers |
US20110117668A1 (en) * | 2009-11-09 | 2011-05-19 | University Of Washington Through Its Center For Commercialization | Self-powered smart diagnostic devices |
US9080933B2 (en) | 2009-11-09 | 2015-07-14 | University Of Washington Through Its Center For Commercialization | Stimuli-responsive polymer diagnostic assay comprising magnetic nanoparticles and capture conjugates |
CN110711249B (en) * | 2019-09-19 | 2020-10-27 | 北京化工大学 | Preparation method of lysosome membrane-coated nanoparticles |
CN114163508A (en) * | 2020-09-11 | 2022-03-11 | 王月志 | Amino acid sequences capable of destroying cells and related nucleotide sequences and related uses |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2209468A (en) * | 1987-09-08 | 1989-05-17 | Univ Salford The | Photosensitive liposomes |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU563827B2 (en) | 1982-07-01 | 1987-07-23 | Millipore Corp. | Filtration apparatus |
US4649151A (en) * | 1982-09-27 | 1987-03-10 | Health Research, Inc. | Drugs comprising porphyrins |
US4704255A (en) | 1983-07-15 | 1987-11-03 | Pandex Laboratories, Inc. | Assay cartridge |
US5066274A (en) * | 1985-04-30 | 1991-11-19 | Nippon Petrochemicals Company, Ltd. | Tetrapyrrole therapeutic agents |
US5076950A (en) | 1985-12-20 | 1991-12-31 | Syntex (U.S.A.) Inc. | Magnetic composition for particle separation |
US4895706A (en) | 1986-10-28 | 1990-01-23 | Costar Corporation | Multi-well filter strip and composite assemblies |
US5095030A (en) * | 1987-01-20 | 1992-03-10 | University Of British Columbia | Wavelength-specific cytotoxic agents |
NO891491D0 (en) * | 1987-08-12 | 1989-04-11 | Peter Nemeth | PROCEDURE FOR RELEASE OF CELL MIXTURES AND TISSUE FOR UNUSUAL POPULATIONS. |
HU204856B (en) | 1987-08-12 | 1992-02-28 | Orszagos Mueszaki Fejlesztesi | Process for releasing cell mixtures and tissues from undesired populations and for producing monoclonal antibody - hematoporphyrin conjugates |
US5284647A (en) * | 1988-03-18 | 1994-02-08 | Schering Aktiengesellschaft | Mesotetraphenylporphyrin complex compounds, process for their production and pharmaceutical agents containing them |
US5256532A (en) | 1988-05-02 | 1993-10-26 | Zynaxis Technologies, Inc. | Methods, reagents and test kits for determination of subpopulations of biological entities |
US4925736A (en) * | 1988-07-06 | 1990-05-15 | Long Island Jewish Medical Center | Topical hematoporphyrin |
GB8905001D0 (en) | 1989-03-04 | 1989-04-19 | Univ Leicester | Screening for natural products of microbial metabolism |
US4935498A (en) * | 1989-03-06 | 1990-06-19 | Board Of Regents, The University Of Texas System | Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles |
US5567687A (en) * | 1989-03-06 | 1996-10-22 | University Of Texas | Texaphyrins and uses thereof |
US5328470A (en) * | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
US5059619A (en) * | 1989-06-14 | 1991-10-22 | Quadra Logic Technologies, Inc. | Stable freeze-dried polyhematoporphyrin ether/ester |
DE3919873A1 (en) | 1989-06-19 | 1990-12-20 | Behringwerke Ag | MAGNETIC PROTEIN CONJUGATES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE |
GB8916859D0 (en) | 1989-07-24 | 1989-09-06 | Dynal As | Hapten linking |
GB8929297D0 (en) | 1989-12-29 | 1990-02-28 | Dynal As | Method of separation |
US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
US5491068A (en) | 1991-02-14 | 1996-02-13 | Vicam, L.P. | Assay method for detecting the presence of bacteria |
US5179120A (en) * | 1991-06-28 | 1993-01-12 | Cytopharm, Inc. | Porphycene compounds for photodynamic therapy |
PL165249B1 (en) * | 1991-10-29 | 1994-11-30 | Wojskowa Akad Tech | Method op obtaining complex salts of hematporphyrine and its derivatives |
US5376546A (en) * | 1991-11-04 | 1994-12-27 | Xoma Corporation | Analogs of ribosome-inactivating proteins |
US5258453A (en) * | 1992-01-21 | 1993-11-02 | University Of Utah | Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light |
EP1126025A3 (en) * | 1992-03-16 | 2002-02-13 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of protein kinase C |
WO1993019199A1 (en) | 1992-03-20 | 1993-09-30 | Celsis Limited | Method and apparatus for the analysis of biological material |
AU4115693A (en) * | 1992-04-24 | 1993-11-29 | Sri International | In vivo homologous sequence targeting in eukaryotic cells |
WO1994007138A1 (en) | 1992-09-14 | 1994-03-31 | Fodstad Oystein | Detection of specific target cells in specialized or mixed cell population and solutions containing mixed cell populations |
ZA938208B (en) * | 1992-11-03 | 1995-01-03 | Gene Shears Pty Ltd | TNF-alpha ribozymes and degradation resistant mRNA derivatives linked to TNF-alpha ribozymes |
FR2700010B1 (en) | 1992-12-24 | 1995-03-17 | Rocher Yves Biolog Vegetale | Method and device for testing the reactivity of cells with regard to products. |
US5374531A (en) | 1993-03-22 | 1994-12-20 | Zynaxis, Inc. | Immunoassay for determination of cells |
US5861310A (en) * | 1993-11-03 | 1999-01-19 | Dana-Farber Cancer Institute | Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor |
US5491084A (en) * | 1993-09-10 | 1996-02-13 | The Trustees Of Columbia University In The City Of New York | Uses of green-fluorescent protein |
US6015897A (en) * | 1993-12-07 | 2000-01-18 | Neorx Corporation | Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota |
US5514340A (en) | 1994-01-24 | 1996-05-07 | Magnetix Biotechnology, Inc. | Device for separating magnetically labelled cells |
NO180658C (en) | 1994-03-10 | 1997-05-21 | Oeystein Fodstad | Method and Device for Detecting Specific Target Cells in Specialized or Mixed Cell Populations and Solutions Containing Mixed Cell Populations |
NO180167C (en) * | 1994-09-08 | 1997-02-26 | Photocure As | Photochemical method for introducing molecules into the cytosol of cells |
US5872007A (en) * | 1995-02-17 | 1999-02-16 | Hybridon, Inc. | CAPL-specific oligonucleotides and methods of inhibiting metastatic cancer |
-
1994
- 1994-09-08 NO NO943327A patent/NO180167C/en not_active IP Right Cessation
-
1995
- 1995-09-04 ES ES95932244T patent/ES2163527T3/en not_active Expired - Lifetime
- 1995-09-04 BR BRPI9508825A patent/BRPI9508825B8/en not_active IP Right Cessation
- 1995-09-04 WO PCT/NO1995/000149 patent/WO1996007432A1/en not_active Application Discontinuation
- 1995-09-04 HU HU9800153A patent/HU222984B1/en active IP Right Grant
- 1995-09-04 DE DE69524238T patent/DE69524238T2/en not_active Expired - Lifetime
- 1995-09-04 MX MX9701676A patent/MX9701676A/en unknown
- 1995-09-04 CZ CZ97658A patent/CZ65897A3/en unknown
- 1995-09-04 NZ NZ509519A patent/NZ509519A/en not_active IP Right Cessation
- 1995-09-04 CN CNB951960652A patent/CN1222309C/en not_active Expired - Lifetime
- 1995-09-04 PT PT95932244T patent/PT783323E/en unknown
- 1995-09-04 US US08/793,794 patent/US5876989A/en not_active Expired - Lifetime
- 1995-09-04 JP JP50940496A patent/JP4148328B2/en not_active Expired - Fee Related
- 1995-09-04 NZ NZ293008A patent/NZ293008A/en not_active IP Right Cessation
- 1995-09-04 AU AU35347/95A patent/AU700797B2/en not_active Expired
- 1995-09-04 AT AT95932244T patent/ATE209507T1/en active
- 1995-09-04 EP EP95932244A patent/EP0783323B1/en not_active Expired - Lifetime
- 1995-09-04 CA CA2199290A patent/CA2199290C/en not_active Expired - Lifetime
- 1995-09-14 KR KR1019970701520A patent/KR100395615B1/en active IP Right Grant
- 1995-09-14 KR KR10-2003-7005142A patent/KR100529967B1/en not_active IP Right Cessation
-
1997
- 1997-03-07 FI FI970983A patent/FI121328B/en not_active IP Right Cessation
-
1998
- 1998-04-24 HK HK98103468A patent/HK1004110A1/en not_active IP Right Cessation
- 1998-09-01 US US09/144,750 patent/US6680301B2/en not_active Expired - Fee Related
-
2002
- 2002-11-01 US US10/286,632 patent/US20030134813A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2209468A (en) * | 1987-09-08 | 1989-05-17 | Univ Salford The | Photosensitive liposomes |
Cited By (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6680301B2 (en) | 1994-09-08 | 2004-01-20 | Photocure As | Transfer of molecules into the cytosol of cells |
US8690818B2 (en) | 1997-05-01 | 2014-04-08 | Ekos Corporation | Ultrasound catheter for providing a therapeutic effect to a vessel of a body |
WO2000054802A3 (en) * | 1999-03-15 | 2002-05-10 | Photocure Asa | Method of expressing antigens on the surface of antigen presenting cells by photochemical internalization |
WO2000054802A2 (en) * | 1999-03-15 | 2000-09-21 | Photocure Asa | Method of expressing antigens on the surface of antigen presenting cells by photochemical internalization |
CN100379450C (en) * | 1999-03-15 | 2008-04-09 | 福多库尔联合股份有限公司 | Method of expressing antigen on the surface of an antigen-presenting cell by photochemical internalisation |
AU771990B2 (en) * | 1999-03-15 | 2004-04-08 | Pci Biotech As | Method of expressing antigens on the surface of antigen presenting cells by photo-chemical internalization |
US9737594B2 (en) | 1999-03-15 | 2017-08-22 | Pci Biotech As | Method of stimulating an immune response |
US8216587B1 (en) | 1999-03-15 | 2012-07-10 | Pci Biotech As | Method of vaccination |
US8507258B2 (en) | 1999-09-09 | 2013-08-13 | Akita Prefectural University | Apparatus for perforating membrane |
US7320885B1 (en) * | 1999-09-09 | 2008-01-22 | Toudai Tlo, Ltd. | Method of perforating membrane and apparatus therefor |
US7223600B2 (en) | 2000-11-29 | 2007-05-29 | The Norwegian Radium Hospital Research Foundation | Photochemical internalization for delivery of molecules into the cytosol |
AU2002222104B2 (en) * | 2000-11-29 | 2007-06-28 | Pci Biotech As | Photochemical internalization for virus-mediated molecule delivery into the cyosol |
US7521239B2 (en) | 2000-11-29 | 2009-04-21 | Pci Biotech As | Photochemical internalization for virus-mediated molecule delivery into the cyosol |
WO2002044395A1 (en) * | 2000-11-29 | 2002-06-06 | Pci Biotech As | Photochemical internalization for virus-mediated molecule delivery into the cyosol |
CZ303792B6 (en) * | 2000-11-29 | 2013-05-09 | Pci Biotech As | Method for introducing a molecule into a cell |
US8008077B2 (en) | 2000-11-29 | 2011-08-30 | Pci Biotech As | Photochemical internalization for delivery of molecules into the cytosol |
KR101180548B1 (en) | 2000-11-29 | 2012-09-06 | 피씨아이 바이오테크 에이에스 | Photochemical Internalization for Virus-Mediated Molecule Delivery into the Cytosol |
WO2002062989A3 (en) * | 2001-02-08 | 2003-03-20 | Sequitur Inc | Methods of light activated release 0f ligands from endosomes |
WO2002062989A2 (en) * | 2001-02-08 | 2002-08-15 | Sequitur, Inc. | Methods of light activated release 0f ligands from endosomes |
US8096419B2 (en) | 2001-08-30 | 2012-01-17 | Pci Biotech As | Compound |
US7662807B2 (en) | 2001-08-30 | 2010-02-16 | The Norwegian Radium Hospital Research Foundation | Sulphonated meso-tetraphenyl chlorins |
US10926074B2 (en) | 2001-12-03 | 2021-02-23 | Ekos Corporation | Catheter with multiple ultrasound radiating members |
US7141044B2 (en) | 2001-12-11 | 2006-11-28 | Ekos Corporation | Alternate site gene therapy |
US10036025B2 (en) | 2002-02-01 | 2018-07-31 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
US9796978B1 (en) | 2002-02-01 | 2017-10-24 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
US9777275B2 (en) | 2002-02-01 | 2017-10-03 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
US10626398B2 (en) | 2002-02-01 | 2020-04-21 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
US10196640B1 (en) | 2002-02-01 | 2019-02-05 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
US10106793B2 (en) | 2002-02-01 | 2018-10-23 | Life Technologies Corporation | Double-stranded oligonucleotides |
US9592250B2 (en) | 2002-02-01 | 2017-03-14 | Life Technologies Corporation | Double-stranded oligonucleotides |
US9943675B1 (en) | 2002-04-01 | 2018-04-17 | Ekos Corporation | Ultrasonic catheter power control |
US8852166B1 (en) | 2002-04-01 | 2014-10-07 | Ekos Corporation | Ultrasonic catheter power control |
US9700622B2 (en) | 2006-07-11 | 2017-07-11 | Pci Biotech As | Method for introducing siRNA into cells by photochemical internalisation |
WO2008007073A2 (en) | 2006-07-11 | 2008-01-17 | Pci Biotech As | Method for introducing sirna into cells by photochemical internalisation |
US11925367B2 (en) | 2007-01-08 | 2024-03-12 | Ekos Corporation | Power parameters for ultrasonic catheter |
US11672553B2 (en) | 2007-06-22 | 2023-06-13 | Ekos Corporation | Method and apparatus for treatment of intracranial hemorrhages |
US9241996B2 (en) | 2008-06-30 | 2016-01-26 | Pci Biotech As | Photochemical internalisation of kinase inhibitors |
WO2011018636A2 (en) | 2009-08-14 | 2011-02-17 | Pci Biotech As | Photochemical internalization method |
US9026203B2 (en) | 2009-08-14 | 2015-05-05 | Pci Biotech As | Photosensitizing compositions |
WO2011018635A2 (en) | 2009-08-14 | 2011-02-17 | Pci Biotech As | Photosensitizing compositions |
US9901636B2 (en) | 2012-05-15 | 2018-02-27 | Pci Biotech As | Conjugate of a photosensitiser and chitosan and uses thereof |
AU2013279748B2 (en) * | 2012-05-15 | 2018-08-02 | Pci Biotech As | Conjugate of a photosensitiser and chitosan and uses thereof |
WO2014139597A1 (en) | 2013-03-15 | 2014-09-18 | Pci Biotech As | Method |
US10610582B2 (en) | 2013-08-28 | 2020-04-07 | Pci Biotech As | Compound and method for vaccination and immunisation |
US10166401B2 (en) | 2013-08-28 | 2019-01-01 | Pci Biotech As | Antigen delivery device and method |
WO2015028541A1 (en) * | 2013-08-28 | 2015-03-05 | Pci Biotech As | Antigen delivery device and method |
WO2015154832A1 (en) | 2014-04-11 | 2015-10-15 | Pci Biotech As | Method of treating melanoma |
US10537639B2 (en) | 2014-08-28 | 2020-01-21 | Pci Biotech As | Compound and method |
WO2016030529A1 (en) | 2014-08-28 | 2016-03-03 | Pci Biotech As | Compound and method |
US11027017B2 (en) | 2015-03-05 | 2021-06-08 | Pci Biotech As | PCI method for generating immune respose to antigenic molecule using checkpoint inhibitor and TLR3 ligand |
US10656025B2 (en) | 2015-06-10 | 2020-05-19 | Ekos Corporation | Ultrasound catheter |
US11740138B2 (en) | 2015-06-10 | 2023-08-29 | Ekos Corporation | Ultrasound catheter |
WO2018069536A1 (en) | 2016-10-14 | 2018-04-19 | Pci Biotech As | Treatment of cholangiocarcinoma with tpcs-2a induced photochemical internalisation of gemcitabine |
US11648287B2 (en) | 2017-11-10 | 2023-05-16 | Academisch Medisch Centrum | Composition for the treatment of intracellular bacterial infection |
WO2019145419A1 (en) * | 2018-01-24 | 2019-08-01 | Pci Biotech As | Method |
US11071778B2 (en) | 2018-07-16 | 2021-07-27 | Dcprime B.V. | Combination product for use in tumor vaccination |
US11052144B2 (en) | 2019-04-25 | 2021-07-06 | Dcprime B.V. | Methods of tumor vaccination |
WO2020217226A1 (en) | 2019-04-25 | 2020-10-29 | Dcprime B.V. | Methods of tumor vaccination |
WO2021191870A1 (en) | 2020-03-27 | 2021-09-30 | Dcprime B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
WO2021191871A1 (en) | 2020-03-27 | 2021-09-30 | Dcprime B.V. | In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
WO2022097068A1 (en) | 2020-11-05 | 2022-05-12 | Dcprime B.V. | Use of tumor-independent antigens in immunotherapies |
WO2022167688A1 (en) | 2021-02-08 | 2022-08-11 | Pci Biotech As | Method of delivering mrna in vivo |
GB202101726D0 (en) | 2021-02-08 | 2021-03-24 | Pci Biotech As | Method |
WO2022190058A1 (en) | 2021-03-12 | 2022-09-15 | Dcprime B.V. | Methods of vaccination and use of cd47 blockade |
WO2023073116A1 (en) | 2021-10-27 | 2023-05-04 | Pci Biotech As | Method |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0783323B1 (en) | Transfer of molecules into the cytosol of cells by photosensitizing compounds | |
Berg et al. | Porphyrin‐related photosensitizers for cancer imaging and therapeutic applications | |
Patrice | Photodynamic therapy | |
Moan | Porphyrin-sensitized photodynamic inactivation of cells: a review | |
Detty et al. | Current clinical and preclinical photosensitizers for use in photodynamic therapy | |
Juzeniene et al. | The history of PDT in Norway: Part one: Identification of basic mechanisms of general PDT | |
Palumbo | Photodynamic therapy and cancer: a brief sightseeing tour | |
Rosenkranz et al. | Targeted intracellular delivery of photosensitizers to enhance photodynamic efficiency | |
Selbo et al. | Photochemical internalisation: a novel drug delivery system | |
AU771990B2 (en) | Method of expressing antigens on the surface of antigen presenting cells by photo-chemical internalization | |
Ricchelli et al. | Meso-substituted tetra-cationic porphyrins photosensitize the death of human fibrosarcoma cells via lysosomal targeting | |
Milanesi et al. | Ultrastructural studies on the mechanism of the photodynamic therapy of tumors | |
van den Bergh | Photodynamic therapy of age-related macular degeneration: History and principles | |
Abels et al. | Targeting of the tumor microcirculation by photodynamic therapy with a synthetic porphycene | |
Alvarez et al. | Pharmacokinetic and tumour-photosensitizing properties of methoxyphenyl porphyrin derivative | |
Prasmickaite et al. | Photochemical Transfection Light-Induced, Site-Directed Gene Delivery | |
CZ9727U1 (en) | A means for modifying cellular, especially tumor processes | |
Kostron et al. | Photodynamic Therapy | |
Wang | Studies of photochemical internalisation: mechanisms and strategies in cancer therapeutics | |
Bøe et al. | Light-directed delivery of nucleic acids | |
Peng | Correlation of intracellular and intratumoral photosensitizer distribution with photodynamic effect | |
Maduray | In vitro photodynamic effect of gallium, indium and iron phthalocyanine chloride on different cancer cell lines | |
Feng | Preparation and Evaluation of Pyropheophorbide a Derivatives | |
Woodhams et al. | Julie Tzu-Wen Wang | |
Reich et al. | Photodynamic therapy of human bladder carcinoma cells in vitro with liposomes as carrier for porphycene: 9-acetamido-2, 7, 12, 17-tetra-n-propylporphycene (AamTPPn) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 95196065.2 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: PV1997-658 Country of ref document: CZ |
|
ENP | Entry into the national phase |
Ref document number: 2199290 Country of ref document: CA Ref document number: 2199290 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 293008 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019970701520 Country of ref document: KR Ref document number: 970983 Country of ref document: FI |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08793794 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995932244 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1995932244 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019970701520 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: PV1997-658 Country of ref document: CZ |
|
WWR | Wipo information: refused in national office |
Ref document number: PV1997-658 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: PUV1998-8748 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: PUV1998-8748 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995932244 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019970701520 Country of ref document: KR |